Issue 141 • April 2024

What’s next for AAV gene therapies in 2024?

Many high-profile adeno-associated virus (AAV) vector gene therapies for neuromuscular and blood disorders are anticipated in 2024.

Feature

Traceability technologies tighten supply chain fakery

Feature

Is HIV-TB coinfection treatment entering a new frontier?

Comment

AD/PD 2024: Eli Lilly’s donanemab hit with FDA delay

Interview

Awareness key for digital therapeutics to realise full potential